GERD and Refractory Reflux: Acid Suppression Drugs

0:00Welcome to Board Pearls. This is episode two of three of the GERD and Refractory Reflux chapter, in the Esophageal Disorders module. Last episode built reflux as a barrier failure and walked the endoscopic grades. This episode is the acid-suppressing drugs, and here the mechanism explains both the strength and, crucially, the timing that decides whether the drug even works.

0:22The acid-making cell in the stomach pumps acid out through a proton pump on its surface, and it's switched on through three receptors: gastrin, histamine, and acetylcholine, all of which funnel down to that one pump. Blocking the pump itself is more effective than blocking any single one of those switches, which is the whole reason proton pump inhibitors heal erosive disease and the older histamine blockers don't.

0:47The histamine blockers, famotidine and the others, relieve mild symptoms in a good fraction of patients but heal erosive disease poorly, and the reason is that within days the cell ramps up its other switches and the histamine block loses its grip. So they're useful for occasional mild symptoms or as a short-term bedtime add-on, with the understanding that they fade. Two footnotes worth carrying: famotidine has the least passage into breast milk and is the preferred one during breastfeeding, and ranitidine was pulled from the market for a contaminant, so it's never the right answer on a current question.

1:22Proton pump inhibitors bind the active pump permanently, but the cell keeps making fresh pumps and the drug itself is cleared from the blood in about ninety minutes, and two consequences of that get tested relentlessly. First, the drug is a prodrug that has to be switched on by acid inside the cell, and acid is only being made when the cell is stimulated, which happens at meals, so the drug has to be taken thirty to sixty minutes before breakfast, and before dinner too if it's twice a day. Taken at bedtime or with food, it misses most of the pumps that are actually switched on, and this is the single most common reason a patient gets wrongly labeled as failing the drug. When a study referred a large group of supposedly refractory patients, a meaningful share got better simply from a structured trial with proper meal timing, meaning they never had refractory disease at all, just wrong timing. So the first move in any apparent drug failure is to check that they're taking it before a meal. The one exception is dexlansoprazole, whose delayed dual release doesn't need strict meal timing. Second, these drugs take three to five days to build to full effect as the inhibition accumulates across newly made pumps, which is why they're useless for on-the-spot symptom relief. Antacids and alginate handle the acute symptom; the proton pump inhibitor does the sustained suppression. One more wrinkle: these drugs are cleared by a liver enzyme that varies a lot between people, so fast metabolizers may need a higher or twice-daily dose, and rabeprazole and esomeprazole are less affected by that variation, which makes them attractive when you suspect it.

2:55Among the standard proton pump inhibitors the strength does differ, and it's worth holding loosely: pantoprazole is the weakest and rabeprazole the strongest, which matters when you're escalating someone, because moving from a weak one to a strong one raises the ceiling before you even add a second daily dose. In practice, once-daily dosing before breakfast heals most erosive disease and controls most symptoms over eight to twelve weeks; you go twice daily for inadequate response, severe disease at the outset, strictures, or Barrett's; and severe erosive disease usually needs ongoing maintenance because reflux comes back within weeks of stopping, generally at the same dose that healed it, while milder disease can be stepped down to the lowest dose that works, or on-demand.

3:35One specific gap worth knowing: most patients on twice-daily dosing still have a stretch at night where the stomach's acid breaks through, the classic patient being someone with good daytime control who wakes at three in the morning burning. A bedtime histamine blocker can be added short-term, with the same caveat that it fades.

3:54Vonoprazan is a genuinely different class, the one acid blocker of its kind approved here, and its mechanism removes most of the proton pump inhibitor's limitations. It blocks the pump by sitting on it reversibly rather than binding permanently, and it blocks both switched-on and switched-off pumps, so it doesn't have to be timed to a meal. It's stable in acid, it's already active rather than a prodrug, it lasts far longer in the blood, around seven to nine hours, and it's cleared by a different liver enzyme so it sidesteps the metabolizer variation. It's substantially stronger than any standard proton pump inhibitor dose, its clearest advantage is in the most severe erosive disease where it heals more of those patients faster, it's also part of newer H. pylori regimens because steadier acid suppression helps the antibiotics work, and its one caution is that there's no breastfeeding data so it's avoided during lactation. The practical bottom line: it's the answer for genuine acid breakthrough in someone who's truly failed twice-daily proton pump inhibitor taken correctly, and especially compelling in severe disease.

4:57On long-term safety, the thing to calibrate is the strength of the evidence. There's a long list of associations from observational studies, B12 and magnesium and iron, C. diff and pneumonia, kidney disease, dementia, and more, and a couple of those, the B12 and magnesium effects, have real mechanisms behind them. But most of the rest came from observational data where the people on long-term therapy are simply sicker to begin with, and when randomized trials looked, the worrying signals largely didn't hold up, with only a modest signal for intestinal infections. So the right response is the lowest effective dose for the shortest duration that controls the disease, not reflexive discontinuation, and the wrong move on a question is stopping the drug in someone with severe erosive disease, a stricture, or Barrett's because of a safety worry; the right move is to confirm the indication still applies and the dose is as low as it can be.

5:54The clopidogrel pairing still shows up, so hold it: clopidogrel is a prodrug activated by the same liver enzyme that clears some proton pump inhibitors, and omeprazole and esomeprazole can blunt its activation in the lab, but the clinical trials haven't shown a real increase in cardiovascular events, so guidance doesn't require avoiding these drugs together. When someone's worried, pick pantoprazole or rabeprazole, which interact less. The vignette is a dual-antiplatelet patient who needs acid suppression for ulcer prevention, and the answer is to choose the low-interaction drug, not to withhold protection. And one housekeeping point: reflux is neither a reason to test for H. pylori nor a reason not to treat it, so a reflux vignette isn't the place to add an H. pylori workup.

6:39So the drug story in sequence. The histamine blockers fade in erosive disease as the cell ramps up its other switches. The proton pump inhibitors are prodrugs that must be taken thirty to sixty minutes before a meal and take days to build up, which makes wrong timing the single most common cause of apparent failure; pantoprazole is the weakest and rabeprazole the strongest, so escalation can mean switching agents before adding a second dose. Vonoprazan blocks the pump directly, ignores meal timing, lasts longer, and is the answer for true failure, especially in severe disease. And the long-term safety scare hasn't survived the randomized data, so the answer is the lowest effective dose, not stopping a drug someone needs.

7:21In the next episode we take the patient whose drug has genuinely failed: the framework that separates proven reflux from an oversensitive but normal esophagus, how you choose antireflux surgery only after you've actually documented reflux, and the reality that working up the refractory patient is mostly working up a diagnosis that turns out not to be reflux at all.

7:42For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of three of chapter three, and I'll see you in the next one.